Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 09, 2024 (filed on Apr 09, 2024)Insider Name:Lippis Daniel J.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Acquire)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-857Price:--
-
Apr 09, 2024 (filed on Apr 09, 2024)Insider Name:Lippis Daniel J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-857Price:$92.34
-
Apr 09, 2024 (filed on Apr 09, 2024)Insider Name:Lippis Daniel J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:857Price:$36.75
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Lemercier Jean-Luc MOwnership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Acquire)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-14,400Price:--
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Lemercier Jean-Luc MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14,293Price:$92.32
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Lemercier Jean-Luc MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-107Price:$92.65
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Lemercier Jean-Luc MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:14,400Price:$36.75
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Bobo Donald E JrOwnership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Acquire)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-12,500Price:--
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Bobo Donald E JrOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-12,400Price:$92.33
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Bobo Donald E JrOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-100Price:$92.66
Filings by filing date
-
Apr 09, 2024 (filed on Apr 09, 2024)Insider Name:Lippis Daniel J.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Acquire)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-857Price:--
-
Apr 09, 2024 (filed on Apr 09, 2024)Insider Name:Lippis Daniel J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-857Price:$92.34
-
Apr 09, 2024 (filed on Apr 09, 2024)Insider Name:Lippis Daniel J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:857Price:$36.75
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Lemercier Jean-Luc MOwnership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Acquire)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-14,400Price:--
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Lemercier Jean-Luc MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14,293Price:$92.32
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Lemercier Jean-Luc MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-107Price:$92.65
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Lemercier Jean-Luc MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:14,400Price:$36.75
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Bobo Donald E JrOwnership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Acquire)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-12,500Price:--
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Bobo Donald E JrOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-12,400Price:$92.33
-
Apr 08, 2024 (filed on Apr 08, 2024)Insider Name:Bobo Donald E JrOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-100Price:$92.66
News
Biz Brief
Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | One Edwards Way IRVINE CA 92614 |
Tel: | N/A |
Website: | https://www.edwards.com |
IR: | See website |
Key People | ||
Bernard J. Zovighian President, Chief Executive Officer | Scott B. Ullem Chief Financial Officer, Corporate Vice President | Wayne Markowitz Senior Vice President, General Manager - Surgical Structural Heart |
Donald E. Bobo Corporate Vice President - Strategy and Corporate Development | Daveen Chopra Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies | Jean-Luc Lemercier Corporate Vice President, EMEACLA (Europe, Middle East, Africa, Canada and Latin America) |
Daniel Lippis Corporate Vice President - JAPAC (Japan, Greater China and Asia Pacific) | Catherine M. Szyman Corporate Vice President - Critical Care | Larry L. Wood Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement |
Business Overview |
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. It conducts operations worldwide and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. It sells products that are used to treat advanced cardiovascular disease in all regions. |
Financial Overview |
For the fiscal year ended 31 December 2023, Edwards Lifesciences Corp revenues increased 12% to $6B. Net income decreased 8% to $1.4B. Revenues reflect Transcatheter Aortic Valve Replacement segment increase of 10% to $3.88B, Surgical Heart Valve Therapy segment increase of 12% to $999.3M, Transcatheter Mitral and Tricuspid Therapies segment increase of 70% to $197.6M, United States segment increase of 12% to $3.51B. |
Employees: | 19,800 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $52,289M as of Dec 31, 2023 |
Annual revenue (TTM): | $6,005M as of Dec 31, 2023 |
EBITDA (TTM): | $1,900M as of Dec 31, 2023 |
Net annual income (TTM): | $1,402M as of Dec 31, 2023 |
Free cash flow (TTM): | $629.50M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 601,926,692 as of Mar 8, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |